AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16440580
Drug: Calcipotriol solution
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol solution 50 g/ml, applied twice daily for 8 weeks
Trial: 10569667
Drug: Theophylline (adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (adenosine receptor antagonist)
Trial: 6364399
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg tendamistate with 100 g maize meal
Trial: 6364399
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tendamistate with 100 g maize meal
Trial: 6364399
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tendamistate with 100 g maize meal
Trial: 6364399
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 100 g maize meal
Trial: 27506971
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BtX‐A) injection (200 IU) in the quadriceps muscles
Trial: 14742982
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements with morning dose of MMF (n=14)
Trial: 14742982
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements given 4 hr after MMF at midday (n=13)
Trial: 14742982
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron supplements (n=13)
Trial: 11577951
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group in surgical treatment
Trial: 11577951
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group in non-surgical treatment
Trial: 9628449
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg IV bolus followed by SC injections of 1.0 mg/kg every 12 hours)
Trial: 9628449
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (70 U/kg bolus followed by infusion of 15 U/kg per hour)
Trial: 9628449
Drug: Enoxaparin (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (fixed-dose SC enoxaparin 60 mg every 12 hours for patients ≤65 kg, 40 mg every 12 hours for patients <65 kg)
Trial: 8051381
Drug: malotilate 1500
RxNorm normalized name: Maltol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: malotilate 1500 mg/day
Trial: 8051381
Drug: malotilate 750
RxNorm normalized name: Maltol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: malotilate 750 mg/day
Trial: 20034170
Drug: Oxazepam (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (60-120 mg daily)
Trial: 31997704
Drug: Nasal administration
RxNorm normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal administration of vasopressin (AVP)
Trial: 21288628
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 μg/drsp 3mg COC (n=451)
Trial: 19473905
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy (Gp B)
Trial: 17093248
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (1.5 mg/kg daily for 5 days)
Trial: 11172151
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy with iridium-192
Trial: 9506734
Drug: Troglitazone (200‐800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200‐800 mg daily)
Trial: 2454038
Drug: Cladosporium immunotherapy
RxNorm normalized name: CLADOSPORIUM
DrugBank: Cladosporium herbarum (DB10865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladosporium immunotherapy
Trial: 1073187
Drug: alexidine dihydrochloride
RxNorm normalized name: Exidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alexidine dihydrochloride oral rinse
Trial: 1073187
Drug: placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral rinse
Trial: 24486163
Drug: Hospital-at-home treatment
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-at-home treatment
Trial: 19936767
Drug: Chronomodulated chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronomodulated chemotherapy
Trial: 16336029
Drug: Tulobuterol (2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol (2mg once-daily applied as a patch)
Trial: 16336029
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg per inhalation, twice a day)
Trial: 11882468
Drug: Milk consumption
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk consumption (mean 50 g/day, 95% CI 44-55 g/day)
Trial: 11882468
Drug: Milk consumption
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk consumption (varied by region: rural 9 g/day, suburban 36 g/day, urban 83 g/day)
Trial: 10612357
Drug: Tiagabine (TGB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB; Gabitril) at doses of 32 mg/day and 56 mg/day
Trial: 10612357
Drug: Tiagabine (TGB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB; Gabitril) administered twice, three times, and four times daily
Trial: 2278377
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine application (0.5-1.0 microgram/kg per min)
Trial: 2278377
Drug: Bolus morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus morphine injections (0.05 mg/kg)
Trial: 6118666
Drug: Intra-articular yttrium-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular yttrium-90 (5 mCi) plus steroid (triamcinolone hexacetonide, 20 mg)
Trial: 6118666
Drug: Saline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline plus steroid (control)
Trial: 30291016
Drug: Multimodality weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality weight gain prevention intervention (10 weekly peer-support sessions)
Trial: 25041234
Drug: Ranolazine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (500 mg twice a day for 8 weeks)
Trial: 24713310
Drug: Tapentadol sustained-release
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol sustained-release (SR) [average daily dose 433 (31) mg]
Trial: 22797188
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg of risedronate weekly
Trial: 15969759
Drug: Calcium-fortified beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-fortified beverage (1,125 mg Ca++/d)
Trial: 9718289
Drug: D-cycloserine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (500 mg)
Trial: 7663789
Drug: Full 24-hour
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full 24-hour lung function profile (thirteen 2-hourly measurements)
Trial: 2758900
Drug: Intrapartum saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum saline amnio-infusion
Trial: 2758900
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no amnio-infusion)
Trial: 435349
Drug: Suxamethonium infusion
RxNorm normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suxamethonium infusion at 0.25 mg s‐1 to 20 mg s‐1
Trial: 435349
Drug: 30-mg i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg i.v. bolus dose of Suxamethonium
Trial: 29240541
Drug: Metastasis-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastasis-directed therapy (MDT)
Trial: 21714697
Drug: Extended letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended letrozole regimen (5 mg/day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days) combined with HPuFSH-GnRHant protocol
Trial: 21714697
Drug: Short letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short letrozole regimen (2.5 mg/day from cycle day 3-7) combined with HPuFSH-GnRHant protocol
Trial: 12201832
Drug: 10, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 15 or 20 mg of pegvisomant
Trial: 11793023
Drug: rosiglitazone, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone, 8 mg/day (n = 15)
Trial: 24316262
Drug: Telaprevir 1125
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir 1125 mg twice daily
Trial: 20194386
Drug: No bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bleaching treatment (controls)
Trial: 17394960
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 120 mg once daily for 7 days
Trial: 17394960
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (24 mg/min) during intra-arterial coinfusion after IS‐5‐MN therapy
Trial: 16240937
Drug: Diazepam (DZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (DZ; 10 mg/d) for 14 days
Trial: 12167793
Drug: Corline Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corline Heparin Surface with standard dose of systemic heparin
Trial: 12167793
Drug: Corline Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corline Heparin Surface with high dose of systemic heparin
Trial: 12167793
Drug: Corline Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corline Heparin Surface with low dose of systemic heparin
Trial: 12167793
Drug: Uncoated surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncoated surface with standard dose of systemic heparin
Trial: 8591104
Drug: Danazol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (400 mg/day orally for 4 to 6 months)
Trial: 27216835
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of ketamine
Trial: 20735290
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg
Trial: 20642544
Drug: Eltrombopag 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 150 mg
Trial: 7524016
Drug: Auditory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory treatment
Trial: 7524016
Drug: Kinesthetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesthetic treatment
Trial: 7524016
Drug: Visual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual treatment
Trial: 3215041
Drug: Intravenous alifedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alifedrine 20 mg
Trial: 3215041
Drug: Intravenous alifedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alifedrine 40 mg
Trial: 3215041
Drug: Oral alifedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alifedrine 40 mg
Trial: 31276430
Drug: Caregiver-reported preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver-reported preventive medication use
Trial: 31276430
Drug: Preventive medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive medication availability at home
Trial: 22854293
Drug: Medication sharing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication sharing
Trial: 31276430
Drug: Filled a
RxNorm normalized name: Prefilled Applicator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filled a preventive medication in the past year (subset with pharmacy records)
Trial: 31276430
Drug: Preventive medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive medication at home (subset with pharmacy records)
Trial: 31276430
Drug: Caregiver report
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver report of no preventive medication use in the past 2 weeks
Trial: 31870325
Drug: Low-dose high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose high-frequency clinical mentorship in EmONC
Trial: 28508306
Drug: Brimonidine Tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine Tartrate 0.1% ophthalmic solution
Trial: 28508306
Drug: Timolol Maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol Maleate 0.5% ophthalmic solution
Trial: 21962451
Drug: Intravenous alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alendronate (125 μg)
Trial: 21962451
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (35 mg)
Trial: 21962451
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral alendronate
Trial: 18974581
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol for eight weeks
Trial: 12827224
Drug: Raloxifene plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene plus MFP (60 mg/day raloxifene HCl and 20 mg/day fluoride ions)
Trial: 12827224
Drug: MFP alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP alone (20 mg/day fluoride and placebo)
Trial: 11096443
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus adjuvant gene therapy during surgery
Trial: 11096443
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (surgical resection and radiotherapy)
Trial: 10326536
Drug: ALM +
RxNorm normalized name: SlowMag Calm + Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALM + BCG (1 mg ALM mixed with BCG)
Trial: 7661605
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg/d)
Trial: 766798
Drug: R &
RxNorm normalized name: R & C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R & S 218‐M 0.56 mg/70 kg
Trial: 766798
Drug: R &
RxNorm normalized name: R & C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R & S 218‐M 0.35 mg/70 kg
Trial: 766798
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 10.5 mg/70 kg
Trial: 6789777
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied chemotherapeutic drugs (e.g., thiotepa, fluorouracil, betamethasone valerate)
Trial: 6789777
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied chemotherapeutic drugs
Trial: 19434360
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day ilaprazole
Trial: 19434360
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day ilaprazole
Trial: 19434360
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (ilaprazole and omeprazole)
Trial: 18693810
Drug: Natural Language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural Language Processing methods to detect trends in medication usage
Trial: 15013946
Drug: Peptide YY3-36
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide YY3-36 (PYY3-36) infusion
Trial: 11762428
Drug: Antidepressant discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant discontinuation during week 8 of 12-week group CBT treatment
Trial: 9826883
Drug: Bath temperature
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bath temperature of 37 degrees C (98.6 degrees F) with UVA doses ranging from 0.5 to 5.5 J/cm2
Trial: 2913139
Drug: Theophylline (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (serum levels of 10 to 20 mg/L)
Trial: 1215448
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg/70 kg) + Ethanol (0.75 g/kg)
Trial: 27311739
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (VR-based motivational visuomotor feedback training with levodopa)
Trial: 25302624
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg and 400 mg
Trial: 25302624
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg, 400 mg, and placebo
Trial: 14724869
Drug: Topical triple
RxNorm normalized name: Triple Paste Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triple antibiotic ointment (TAO)
Trial: 8082050
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day of elemental calcium in the form of calcium pidolate
Trial: 28799056
Drug: Single-dose botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose botulinum toxin type A (BTX-A) injection of 70 to 100 U
Trial: 28799056
Drug: Repeated-dose botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated-dose botulinum toxin type A (BTX-A) injection of 50 to 70 U initially, followed by another of equal volume 2 weeks later
Trial: 21164169
Drug: DDAVP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (1 μg/kg, intravenous)
Trial: 19552493
Drug: Post-fracture use
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-fracture use of prescribed calcium plus vitamin D supplements
Trial: 19552493
Drug: Post-fracture use
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-fracture use of anti-osteoporotic drugs concomitantly with calcium plus vitamin D
Trial: 19552493
Drug: Neither anti-osteoporotic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither anti-osteoporotic drugs nor prescribed calcium and vitamin D
Trial: 15280750
Drug: p-GlcNAc patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-GlcNAc patch
Trial: 11552913
Drug: Nitazoxanide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years)
Trial: 11552913
Drug: Metronidazole (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (125 mg b.d. for age 2-5 years; 250 mg b.d. for age 6-11 years)
Trial: 8998124
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human growth hormone (0.5 international units/kg per week)
Trial: 29301450
Drug: SonoVue (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (1.5 ml) before HIFU ablation
Trial: 29301450
Drug: Saline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1.5 ml) before HIFU ablation
Trial: 25586282
Drug: Levosimendan (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (loading dose of 15 μg/kg/min for 20 minutes, maintenance dose of 0.2 μg/kg/min for 6 hours before anesthetic induction)
Trial: 25586282
Drug: Dopamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (10 μg/kg/min) and/or dobutamine (10 μg/kg/min) during weaning from cardiopulmonary bypass
Trial: 15562385
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/d)
Trial: 12569285
Drug: Hypoxic pelvic
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic pelvic and limb perfusion with 50 mg/m² of melphalan
Trial: 12569285
Drug: Hypoxic pelvic
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxic pelvic and limb perfusion with 50 mg/m² of melphalan and 25 mg/m² of mitomycin C
Trial: 8558148
Drug: Entacapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (200 mg) with levodopa